Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Total Liabilities & Equity

Total Liabilities & Equity at other companies

Pfizer logo
PfizerPFE
$207.62B-0.2%
Amgen logo
AmgenAMGN
$95.64B+8.8%
Incyte logo
IncyteINCY
$7.87B+35.2%
PVL
Palvella TherapeuticsPVLA
$263.76M+232%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$782.35M+13.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$1.65B+45.5%

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.32B+81.4%
Enterprise value$3.4B+82.1%
P/S7.2×+0.2×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock, $0.0001 par value; 300,000 shares authorized at June 30, 2026 and December 31, 2025; 125,591 and 123,333 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1212
Additional paid-in capital1,355,5931,327,595
Accumulated other comprehensive income (loss)(656)(44)
Accumulated deficit(1,134,370)(1,138,084)
Total stockholders’ equity220,579189,479
Total liabilities and stockholders’ equity$488,537$432,973

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s total liabilities & equity?
Arcutis Biotherapeutics, Inc. (ARQT) reported total liabilities & equity of $488.54M in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s total liabilities & equity changed year-over-year?
Arcutis Biotherapeutics, Inc.'s total liabilities & equity increased by 38.6% year-over-year, from $352.43M to $488.54M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s total liabilities & equity has grown at a 7.7% compound annual growth rate (CAGR), from $298.27M to $432.97M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Arcutis Biotherapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude